[Myeloid/lymphoid Neoplasms with Eosinophilia and FGFR1 Rearrangement: 5 Cases Report and Literatures Review]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2019 Nov 29

PMID 31775485

Authors

Y T Liu

J W Zhao

J Feng

Q H Li

Y M Chen

L G Qiu

Z J Xiao

Y Li

B F Gong

X Y Gong

Y C Mi

J X Wang

Affiliations

Soon will be listed here.

Abstract

To investigate the clinic-pathological features, diagnosis and treatment of 8p11 myeloproliferative syndrome (EMS) . Five patients diagnosed as EMS from Jan 2014 to May 2018 at Blood Disease Hospital, Chinese Academy of Medical Sciences were enrolled. The clinical manifestations, laboratory characteristics, treatment and outcome of these patients were summarized. The peripheral blood leukocyte count of 5 patients with EMS increased significantly, accompanied with an elevated absolute eosinophils value (the average as 18.89×10(9)/L) . The hypercellularity of myeloid cells was common in bone marrow, always with the elevated proportion of eosinophils (the average as 17.24%) , but less than 5% of blast cells. The chromosome karyotype of the 5 cases differed from each other, but presenting with the same rearrangement of FGFR1 gene by fluorescence in situ hybridization technology. The average interval between onset and diagnosis was 4.8 months with a median survival of only 14 months. EMS was a rare hematologic malignancy with poor prognosis and short survival. It was commonly to be misdiagnosed. Analysis of cytogenetics and molecular biology were helpful for early diagnosis.

References

Vizmanos J, Hernandez R, Vidal M, Larrayoz M, Odero M, Marin J . Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. Hematol J. 2004; 5(6):534-7. DOI: 10.1038/sj.thj.6200561. View

Demiroglu A, Steer E, Heath C, Taylor K, Bentley M, Allen S . The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001; 98(13):3778-83. DOI: 10.1182/blood.v98.13.3778. View

Grand E, Grand F, Chase A, Ross F, Corcoran M, Oscier D . Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer. 2004; 40(1):78-83. DOI: 10.1002/gcc.20023. View

Bae S, Kim J, Han E, Lee H, Ryeu B, Lee K . Cytogenetic abnormality involving 8p11.2 in T-lymphoblastic lymphoma: report of a new case. Cancer Genet Cytogenet. 2009; 191(1):57-8. DOI: 10.1016/j.cancergencyto.2009.02.003. View

Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billstrom R, Isaksson M . Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer. 2001; 32(4):302-10. DOI: 10.1002/gcc.1195. View

Wehrli M, Oppliger Leibundgut E, Gattiker H, Manz M, Muller A, Goede J . Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and - Rearrangement. Oncologist. 2017; 22(4):480-483. PMC: 5388377. DOI: 10.1634/theoncologist.2016-0354. View

Chen J, DeAngelo D, Kutok J, Williams I, Lee B, Wadleigh M . PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004; 101(40):14479-84. PMC: 521956. DOI: 10.1073/pnas.0404438101. View

Zhou L, Fu W, Yuan Z, Hou J . Complete molecular remission after interferon alpha treatment in a case of 8p11 myeloproliferative syndrome. Leuk Res. 2010; 34(11):e306-7. DOI: 10.1016/j.leukres.2010.06.027. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

10.

Zhang W, Habeebu S, Sheehan A, Naeem R, Hernandez V, Dreyer Z . Molecular monitoring of 8p11 myeloproliferative syndrome in an infant. J Pediatr Hematol Oncol. 2009; 31(11):879-83. DOI: 10.1097/MPH.0b013e3181b83fd0. View

11.

Li F, Zhai Y, Tang Y, Wang L, Wan P . Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer. 2012; 51(9):890-7. DOI: 10.1002/gcc.21973. View

12.

Jackson C, Medeiros L, Miranda R . 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010; 41(4):461-76. DOI: 10.1016/j.humpath.2009.11.003. View

13.

Gervais C, Dano L, Perrusson N, Helias C, Jeandidier E, Galoisy A . A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm. Leukemia. 2012; 27(5):1186-8. DOI: 10.1038/leu.2012.286. View

14.

Guasch G, Popovici C, Mugneret F, Chaffanet M, Pontarotti P, Birnbaum D . Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood. 2002; 101(1):286-8. DOI: 10.1182/blood-2002-02-0577. View

15.

Chase A, Grand F, Cross N . Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007; 110(10):3729-34. DOI: 10.1182/blood-2007-02-074286. View

16.

Dolan M, Cioc A, Cross N, Neglia J, Tolar J . Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. Pediatr Blood Cancer. 2011; 59(1):194-6. DOI: 10.1002/pbc.23404. View

17.

Buijs A, van Wijnen M, van den Blink D, van Gijn M, Klein S . A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment. Cancer Genet. 2013; 206(4):140-4. DOI: 10.1016/j.cancergen.2013.04.001. View

18.

Chaffanet M, Popovici C, Leroux D, Jacrot M, Adelaide J, Dastugue N . t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12. Oncogene. 1998; 16(7):945-9. DOI: 10.1038/sj.onc.1201601. View

19.

Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P . The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica. 2011; 96(6):922-6. PMC: 3105656. DOI: 10.3324/haematol.2010.036558. View

20.

Landberg N, Dreimane A, Rissler M, Billstrom R, Agerstam H . Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. Eur J Haematol. 2017; 99(5):442-448. DOI: 10.1111/ejh.12957. View